U.S. Women’s Health Market Size, Share & Trends Analysis Report By Application (Hormonal Infertility, Contraceptives, Postmenopausal Osteoporosis), By Age, By Drug, By Distribution Channel, And Segment Forecasts, 2023 - 2030

Table of Contents

Chapter 1. Methodology and Scope
                   1.1. Market Segmentation and Scope
                   1.2. Market Definitions
                       1.2.1. Application Segment
                       1.2.2. Age Segment
                       1.2.3. Drug Segment
                       1.2.4. Distribution Channel Segment
                   1.3. Regional Scope
                   1.4. Estimates and Forecast Timeline
                   1.5. Objectives
                       1.5.1. Objective - 1
                       1.5.2. Objective - 2
                       1.5.3. Objective - 3
                   1.6. Research Methodology
                   1.7. Information Procurement
                       1.7.1. Purchased Database
                       1.7.2. GVR’s Internal Database
                       1.7.3. Secondary Sources
                       1.7.4. Primary Research
                   1.8. Information or Data Analysis
                       1.8.1. Data Analysis Models
                   1.9. Market Formulation & Validation
                   1.10. Model Details
                       1.10.1. Commodity Flow Analysis
                   1.11. List of Secondary Sources
                   1.12. List of Abbreviations
Chapter 2. Executive Summary
                   2.1. Market Snapshot
                   2.2. Drug and Application Snapshot
                   2.3. Age and Distribution Channel Snapshot
                   2.4. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
                   3.1. Market Lineage Outlook
                       3.1.1. Parent Market Outlook
                       3.1.2. Related/Ancillary Market Outlook
                   3.2. Market Dynamics
                       3.2.1. Market Driver Analysis
                           3.2.1.1. Increasing prevalence of target diseases
                           3.2.1.2. Child or early marriages
                           3.2.1.3. Increasing initiatives by the government and various organizations
                           3.2.1.4. Rising publicly funded family planning services
                       3.2.2. Market Restraint Analysis
                           3.2.2.1. Patent expiry of major drugs
                           3.2.2.2. Lawsuits related to products
                           3.2.2.3. Adverse effects associated with the use of contraceptive drugs and devices
                   3.3. SWOT Analysis, by Factor
                   3.4. Industry Analysis- Porter’s
                   3.5. Consumer Behaviour Analysis
                   3.6. Target Disease Population
                   3.7. Regulatory Scenario
                   3.8. Reimbursement Scenario
                   3.9. Unmet Needs and Opportunity Analysis
                   3.10. KOL Responses
Chapter 4. Drug Business Analysis
                   4.1. U.S. Women’s Health Market: Drug Movement Analysis
                   4.2. ACTONEL
                       4.2.1. ACTONEL Market, 2018 - 2030 (USD Million)
                   4.3. YAZ, Yasmin, Yasminelle
                       4.3.1. YAZ, Yasmin, Yasminelle Market, 2018 - 2030 (USD Million)
                   4.4. FORTEO
                       4.4.1. FORTEO Market, 2018 - 2030 (USD Million)
                   4.5. Minastrin 24 FE
                       4.5.1. Minastrin 24 Fe Market, 2018 - 2030 (USD Million)
                   4.6. Mirena
                       4.6.1. Mirena Market, 2018 - 2030 (USD Million)
                   4.7. NuvaRing
                       4.7.1. NuvaRing Market, 2018 - 2030 (USD Million)
                   4.8. ORTHO TRI-CY LO
                       4.8.1. ORTHO TRI-CY LO Market, 2018 - 2030 (USD Million)
                   4.9. Premarin
                       4.9.1. Premarin Market, 2018 - 2030 (USD Million)
                   4.10. Prolia
                       4.10.1. Prolia Infections Market, 2018 - 2030 (USD Million)
                   4.11. Reclast/Aclasta
                       4.11.1. Reclast/Aclasta Market, 2018 - 2030 (USD Million)
                   4.12. XGEVA
                       4.12.1. XGEVA Market, 2018 - 2030 (USD Million)
                   4.13. Zometa
                       4.13.1. Zometa Market, 2018 - 2030 (USD Million)
                   4.14. Others
                       4.14.1. Others Market, 2018 - 2030 (USD Million)
Chapter 5. Application Business Analysis
                   5.1. U.S. Women’s Health Market: Application Movement Analysis
                   5.2. Hormonal Infertility
                       5.2.1. Hormonal Infertility Market, 2018 - 2030 (USD Million)
                   5.3. Contraceptives
                       5.3.1. Contraceptives Market, 2018 - 2030 (USD Million)
                   5.4. Postmenopausal Osteoporosis
                       5.4.1. Postmenopausal Osteoporosis Market, 2018 - 2030 (USD Million)
                   5.5. Endometriosis & Uterine Fibroids
                       5.5.1. Endometriosis & Uterine Fibroids Market, 2018 - 2030 (USD Million)
                   5.6. Menopause
                       5.6.1. Menopause Market, 2018 - 2030 (USD Million)
                   5.7. Polycystic Ovary Syndrome (PCOS)
                       5.7.1. Polycystic Ovary Syndrome (PCOS) Market, 2018 - 2030 (USD Million)
Chapter 6. Age Business Analysis
                   6.1. U.S. Women’s Health Market: Age Movement Analysis
                   6.2. 50 Years and Above
                       6.2.1. 50 Years and Above Market, 2018 - 2030 (USD Million)
                   6.3. Others
                       6.3.1. Others Market, 2018 - 2030 (USD Million)
Chapter 7. Distribution Channel Business Analysis
                   7.1. U.S. Women’s Health Market: Distribution Channel Movement Analysis
                   7.2. Hospital Pharmacy
                       7.2.1. Hospital Pharmacy Market, 2018 - 2030 (USD Million)
                   7.3. Retail Pharmacy
                       7.3.1. Retail Pharmacy Market, 2018 - 2030 (USD Million)
                   7.4. Online Pharmacy
                       7.4.1. Online Pharmacy Market, 2018 - 2030 (USD Million)
Chapter 8. Competitive Landscape
                   8.1. Company Categorization
                   8.2. Strategy Mapping
                   8.3. Company Market Share Analysis, 2022
                   8.4. Company Profiles/Listing
                       8.4.1. AbbVie Inc.,
                           8.4.1.1. Overview
                           8.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                           8.4.1.3. Product Benchmarking
                           8.4.1.4. Strategic Initiatives
                       8.4.2. Bayer AG
                           8.4.2.1. Overview
                           8.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                           8.4.2.3. Product Benchmarking
                           8.4.2.4. Strategic Initiatives
                       8.4.3. Merck & Co., Inc. (ORGANON)
                           8.4.3.1. Overview
                           8.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                           8.4.3.3. Product Benchmarking
                           8.4.3.4. Strategic Initiatives
                       8.4.4. Pfizer, Inc.
                           8.4.4.1. Overview
                           8.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                           8.4.4.3. Product Benchmarking
                           8.4.4.4. Strategic Initiatives
                       8.4.5. Teva Pharmaceutical Industries Ltd.
                           8.4.5.1. Overview
                           8.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                           8.4.5.3. Product Benchmarking
                           8.4.5.4. Strategic Initiatives
                       8.4.6. Agile Therapeutics, Inc.
                           8.4.6.1. Overview
                           8.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                           8.4.6.3. Product Benchmarking
                           8.4.6.4. Strategic Initiatives
                       8.4.7. Amgen, Inc.
                           8.4.7.1. Overview
                           8.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                           8.4.7.3. Product Benchmarking
                           8.4.7.4. Strategic Initiatives
                       8.4.8. Apothecus Pharmaceutical Corp.
                           8.4.8.1. Overview
                           8.4.8.2. Product Benchmarking
                           8.4.8.3. Strategic Initiatives
                       8.4.9. Lilly (Eli Lilly)
                           8.4.9.1. Overview
                           8.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                           8.4.9.3. Product Benchmarking
                           8.4.9.4. Strategic Initiatives
                       8.4.10. Ferring B.V.
                           8.4.10.1. Overview
                           8.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                           8.4.10.3. Product Benchmarking
                           8.4.10.4. Strategic Initiatives

List of Tables

TABLE 1 List of Secondary Sources
TABLE 2 List of Abbreviations
TABLE 3 Funding by organizations
TABLE 4 Key sources for contraceptives procurement in the U.S., 2021
TABLE 5 Patent expiry of major drugs
TABLE 6 Contraceptives methods and associated side effects
TABLE 7 U.S. women’s health market revenue estimated and forecast, by drug, 2018 - 2030 (USD million)
TABLE 8 U.S. women’s health market revenue estimated and forecast, by application, 2018 - 2030 (USD million)
TABLE 9 Treatment/Remedies for menopause symptoms management
TABLE 10 Menopause consumer survey
TABLE 11 U.S. women’s health market revenue estimated and forecast, by age, 2018 - 2030 (USD million)
TABLE 12 U.S. women’s health market revenue estimated and forecast, by distribution channel, 2018 - 2030 (USD million)
TABLE 13 Company market share, 2022

List of Figures

FIG. 1 Market Research Process
FIG. 2 Information Procurement
FIG. 3 Primary Research Pattern
FIG. 4 Market Research Approaches
FIG. 5 Value Chain-Based Sizing & Forecasting
FIG. 6 Market Formulation & Validation
FIG. 7 U.S. Women’s Health Market Segmentation
FIG. 8 Market Driver Relevance Analysis (Current & Future Impact)
FIG. 9 Market Restraint Relevance Analysis (Current & Future Impact)
FIG. 10 Market Challenge Relevance Analysis (Current & Future Impact)
FIG. 11 Penetration & Growth Prospect Mapping
FIG. 12 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
FIG. 13 Porter’s Five Forces Analysis
FIG. 14 U.S. women’s health market: Drug outlook and key takeaways
FIG. 15 U.S. women’s health market: Drug movement analysis & market share 2022 & 2030
FIG. 16 ACTONEL market, 2018 - 2030 (USD Million)
FIG. 17 YAZ, Yasmin, Yasminelle market, 2018 - 2030 (USD Million)
FIG. 18 FORTEO market, 2018 - 2030 (USD Million)
FIG. 19 Minastrin 24 Fe market, 2018 - 2030 (USD Million)
FIG. 20 Mirena market, 2018 - 2030 (USD Million)
FIG. 21 NuvaRing market, 2018 - 2030 (USD Million)
FIG. 22 ORTHO TRI-CY LO market, 2018 - 2030 (USD Million)
FIG. 23 Premarin market, 2018 - 2030 (USD Million)
FIG. 24 Prolia market, 2018 - 2030 (USD Million)
FIG. 25 Reclast/Aclasta market, 2018 - 2030 (USD Million)
FIG. 26 XGEVA market, 2018 - 2030 (USD Million)
FIG. 27 Zometa market, 2018 - 2030 (USD Million)
FIG. 28 U.S. women’s health market: Application outlook and key takeaways
FIG. 29 U.S. women’s health market: Application movement analysis & market share 2022 & 2030
FIG. 30 Hormonal infertility market, 2018 - 2030 (USD Million)
FIG. 31 Contraceptives market, 2018 - 2030 (USD Million)
FIG. 32 Postmenopausal osteoporosis market, 2018 - 2030 (USD Million)
FIG. 33 Endometriosis & uterine fibroids market, 2018 - 2030 (USD Million)
FIG. 34 Menopause market, 2018 - 2030 (USD Million)
FIG. 35 Polycystic ovary syndrome (PCOS) market, 2018 - 2030 (USD Million)
FIG. 36 U.S. women’s health market: Age outlook and key takeaways
FIG. 37 U.S. women’s health market: Age movement analysis & market share 2022 & 2030
FIG. 38 50 years and above market, 2018 - 2030 (USD Million)
FIG. 39 Others market, 2018 - 2030 (USD Million)
FIG. 40 U.S. women’s health market: Distribution channel outlook and key takeaways
FIG. 41 U.S. women’s health market: Distribution channel movement analysis & market share 2022 & 2030
FIG. 42 Hospital pharmacy market, 2018 - 2030 (USD Million)
FIG. 43 Retail pharmacy market, 2018 - 2030 (USD Million)
FIG. 44 Online pharmacy market, 2018 - 2030 (USD Million)
FIG. 45 Strategy Mapping